Pioglitazone, a PPARγ agonist, enhanced the therapeutic effects of adipose tissue-derived regenerative cells on chronic myocardial infarction by stimulating adiponectin paracrine activity and M2 macrophage polarization [50]. Here, PPARG is linked to myocardial infarction.